Use of radioimmunoassay of digitalis glycosides in man. 1976

M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D004071 Digitalis Glycosides Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis. Glycosides, Digitalis
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
July 1981, Planta medica,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
June 1973, Pharmacological reviews,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
February 1974, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
February 1976, American journal of hospital pharmacy,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
March 1948, Federation proceedings,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
December 1975, The Journal of the Maine Medical Association,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
January 1982, Duodecim; laaketieteellinen aikakauskirja,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
November 1976, La Revue du praticien,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
January 1947, Hahnemann monthly,
M G Bogaert, and F M Belpaire, and M M Mussche, and J P van Durme
January 1959, Orvosi hetilap,
Copied contents to your clipboard!